Treatment library
Short explainers, then source links.
Each treatment page starts with a plain-language overview, then links to studies, source pages, or registries. Availability and approval can vary by country.
Surgery in melanoma
Surgery conversations often focus on what is being removed, margins, sentinel lymph node biopsy, and what the final pathology might change.
Tunlametinib / HL-085
Tunlametinib is a selective MEK1/2 inhibitor studied in advanced NRAS-mutant melanoma. MatchMedi treats it as China-specific and source-dependent, not a global standard option.
MEK inhibitors in melanoma
MEK is part of a signaling pathway that can be active in some melanoma mutations. The relevance of a MEK inhibitor depends on the mutation, drug, country, prior treatment, and trial or approval status.
Immune checkpoint inhibitors
Immunotherapy can help the immune system recognize and attack melanoma, but it can also cause immune-related side effects.
Lifileucel / TIL therapy
TIL therapy is different from ordinary checkpoint immunotherapy. A tumor sample is used to grow a patient's own immune cells outside the body, then the cells are given back through a specialized treatment program.
Nivolumab + relatlimab
This combines two immune checkpoint targets: PD-1 and LAG-3. It belongs in immunotherapy conversations and should not be confused with MEK-targeted therapy.
BRAF + MEK combinations
These combinations target the MAPK pathway in BRAF V600 melanoma. They are grouped here so families can separate BRAF-targeted therapy from NRAS MEK-inhibitor research.
Chemotherapy in melanoma
Chemotherapy may still come up in selected situations, especially after other options or in specific local protocols, but it is not the center of many modern melanoma treatment plans.
Radiation and local therapy in melanoma
Local treatments focus on a specific tumor area rather than the whole body. They may be paired with systemic therapy conversations.
Clinical trials in melanoma
Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.